The primary market welcomes a new player in the pharmaceutical space as Corona Remedies Ltd opens its initial public offering for subscription today, December 8, 2025. This marks a significant event for investors looking to gain exposure to a company with a diversified portfolio in critical healthcare segments.
Corona Remedies IPO: Key Dates and Financial Details
The public issue will remain open for subscription for three days, closing on Wednesday, December 10, 2025. Following the closure, the basis of allotment is tentatively scheduled for December 11. Successful allottees can expect the shares to be listed and commence trading on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on December 15, 2025.
The company has set a price band of ₹1,008 to ₹1,062 for each equity share. At the upper end of this band, the IPO aims to mobilize ₹655.37 crore. It is crucial to note that this is entirely an offer for sale (OFS) of 61.71 lakh shares by existing promoters and shareholders, meaning the company will not receive fresh capital from this issue.
For retail investors, the minimum application size is one lot, which consists of 14 shares. This translates to a minimum investment amount of ₹14,868 at the upper price band. JM Financial Ltd. is managing the book-building process as the book running lead manager, while Bigshare Services Pvt. Ltd. has been appointed as the official registrar for the issue.
Strong Grey Market Premium Signals Bullish Sentiment
Ahead of the public subscription, the unofficial grey market has shown robust demand for Corona Remedies shares. According to market trackers, the Grey Market Premium (GMP) for the IPO stands at a substantial ₹290 per share on the opening day.
This premium indicates that shares are trading unofficially at approximately ₹1,352, which is a significant 27.31% premium over the upper issue price of ₹1,062. A strong GMP often reflects high investor appetite and expectations of a healthy listing gain, though it is an unofficial indicator and not a guarantee of post-listing performance.
About Corona Remedies and Investor Takeaway
Corona Remedies Ltd is an established pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of formulations. The company has a strategic focus on therapeutic areas including women’s healthcare, cardiology, pain management, and urology, among others. This diversification across essential treatment segments forms the core of its business model.
The opening of this IPO provides public market investors an opportunity to own a stake in this pharma firm. The combination of a defined price band, clear issue dates, and the positive signal from the grey market sets the stage for an actively subscribed public offering. Investors are advised to carefully review the company's Red Herring Prospectus (RHP) containing all financials and risk factors before making an investment decision.
